University of Oxford
http://www.ox.ac.uk/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From University of Oxford
Finance Watch: More Than $2.5bn In New VC Funding, Capital For Pharma Manufacturing In Africa
Private Company Edition: J.P. Morgan raised more than $500m in its first venture fund and the Africa Health Security Investment Plan gained $2bn. Also, Marea launched with $190m, Iambic’s series B expanded to $150m, InduPro raised an $85m series A and Elion closed an $81m series B.
Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout
Plus deals involving Immunis/Toray, AstraZeneca/Nona, Swixx/Biopas, Deimos/G1, Serum Institute of India/IntegriMedical/ImmunityBio plus tech transfer agreements and deals in brief.
BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs
Bristol Myers Squibb CEO Christopher Boerner is looking to India to house the the company’s largest R&D site outside of the US, channeling the country's IT expertise to expand its AI-driven small-molecule research. He also wants to bring its drugs to treat multiple sclerosis and Lupus to India.
Emergex CEO Questions mRNA Vaccines Against ‘Wuhan Virus’, Works On Universal Vaccines
Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
Company Information
- Industry
- Academic and Research Institutions
- Other Names / Subsidiaries
-
- Oxford University Innovation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice